Table 3.

Multivariate analysis of predictors for achieving sustained remission (OR and 95% CI). Significant data are given in bold face.

VariableBoolean Clinical Trial DefinitionBoolean Clinical Practice DefinitionSDAI
Age, yrs0.99 (0.98, 1.00)0.99 (0.98, 1.00)0.99 (0.98, 1.00)
Sex (female vs male)0.74 (0.49, 1.11)0.58 (0.40, 0.86)0.96 (0.66, 1.4)
Smoker (current vs never)0.63 (0.37, 1.06)1.02 (0.85, 1.23)0.84 (0.50, 1.38)
Smoker (ex-smoker vs never)0.97 (0.65, 1.44)1.08 (0.74, 1.58)
Symptom duration, mos1.05 (0.99, 1.12)1.04 (0.98, 1.09)1.03 (0.97, 1.09)
Baseline DAS28-ESR, mean score1.03 (0.91, 1.16)1.13 (0.97, 1.32)1.02 (0.89, 1.16)
Baseline pain, mean score0.99 (0.98, 0.99)
Baseline fatigue, mean score0.99 (0.99, 1.00)
No initial DMARD use (yes vs no)0.41 (0.22, 0.76)
Initial use of oral corticosteroids (yes vs no)0.48 (0.32, 0.73)0.64 (0.44, 0.92)0.54 (0.37, 0.80)
Initial use of combination DMARD (yes vs no)1.58 (1.09, 2.28)1.51 (1.07, 2.13)
Time to remission, mos0.94 (0.92, 0.96)0.94 (0.92, 0.96)0.94 (0.92, 0.95)
  • All variables significant in univariate analyses according to selection rule p < 0.10 were entered into multivariate logistic regression analyses. DAS28-ESR: 28-joint Disease Activity Score using erythrocyte sedimentation rate; DMARD: disease-modifying antirheumatic drug; SDAI: Simplified Disease Activity Index.